Cell-Free Cartilage Scaffold Guides Bone Regrowth, Moving Toward Off-the-Shelf Grafts
Researchers developed a cell-free cartilage scaffold that guides bone regeneration without strong immune reactions. The off-the-shelf graft, tested in animals, could replace costly patient-specific grafts. Human trials are being prepared.
Researchers at Lund University in Sweden have engineered a cell-free cartilage scaffold that guides the body to rebuild damaged bone, according to a new study in Proceedings of the National Academy of Sciences. The transplant promotes bone healing without provoking strong immune reactions and has been tested successfully in animal models, with human studies now being prepared.
When large sections of bone are destroyed or removed after cancer treatment, severe joint diseases such as rheumatoid arthritis and osteoarthritis, or serious infections, the body may struggle to repair the damage on its own. Researchers estimate that more than two million people worldwide require bone graft procedures each year. Current treatments usually depend on using a patient's own tissue or cells, an approach that is expensive, time consuming, and can add to the physical burden patients already face, as well as rising healthcare costs.
To develop the new method, the team first grew cartilage tissue in the laboratory and then removed all living cells in a process called decellularization. This leaves behind the extracellular matrix, the natural framework that provides structural support and biological signals. Because the framework remains intact, it still contains growth factors that can guide the body's own cells. When placed at an injury site, the remaining cartilage structure acts like a blueprint that helps the body rebuild damaged bone step by step.
The cartilage structure is based on stable, well-controlled and reproducible cell lines, and can stimulate bone formation without triggering strong immune reactions. The researchers describe it as a ready-made, 'off-the-shelf' graft that interacts with the immune system and can repair large bone defects. Because the material can be produced in advance and stored, it represents an important step toward future clinical use of human bone tissue transplants.
A universal, non-patient-specific approach in tissue engineering with a reproducible manufacturing process offers major advantages over costly and time-consuming patient-specific grafts, the researchers note. The next phase of research will focus on evaluating the method in people while expanding and standardizing production. This includes deciding which injuries to test first, such as severe defects in long bones of the arms and legs, developing documentation for ethical review and regulatory approval to conduct clinical trials, and establishing a manufacturing process that can be carried out on a larger scale while maintaining quality and safety.